NCT03795012 is a Phase 2 clinical trial of Eribulin in Breast Cancer, sponsored by MedSIR.

Who is sponsoring NCT03795012?

NCT03795012 is sponsored by MedSIR.

What drugs are being tested in NCT03795012?

Interventions in NCT03795012: Eribulin.

What condition does NCT03795012 study?

NCT03795012 studies Breast Cancer.

Is NCT03795012 still recruiting?

NCT03795012 is currently terminated. Last updated 31 August 2021.

Last reviewed 2021-08-31 · How we verify

NCT03795012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Terminated Phase 2 Last updated 31 August 2021

What this trial tests

Phase 2 trial testing Eribulin in Breast Cancer in 22 participants. Terminated before completion.

Timeline

30 April 2019

Primary endpoint
31 March 2021

31 March 2021

Quick facts

Lead sponsor	MedSIR
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	30 April 2019
Primary completion	31 March 2021
Estimated completion	31 March 2021
Sites	9 locations across Spain

Drugs / interventions tested

Eribulin (ERIBULIN) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

MedSIR — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer.
El-Sahli S, Wang L. · · 2020 · cited 32× · PMID 33266219 · DOI 10.3390/ijms21239125
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
Pascual T, Oliveira M, Villagrasa P, Ortega V, et al · · 2021 · cited 16× · PMID 34824288 · DOI 10.1038/s41523-021-00351-4
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective.
Yuan P, Xu B, Xu B. · · 2021 · cited 7× · PMID 33658845 · DOI 10.2147/bctt.s231298
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
López González A, Del Barco Berrón S, Grau I, Galan M, et al · · 2022 · cited 4× · PMID 36497361 · DOI 10.3390/cancers14235880

Verify or expand the search:

Other trials of Eribulin

Trials testing the same drug.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06957431 — Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma · Phase 1 · recruiting
NCT06942234 — Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer · Phase 2 · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other MedSIR trials

Trials by the same sponsor.

NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07178938 — Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases · Phase 2 · not yet recruiting
NCT05708235 — A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · Phase 2 · recruiting
NCT05659563 — Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% · Phase 2 · completed
NCT05520723 — Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03795012 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedSIR
Last refreshed: 31 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing